THE WHAT? Croda has announced the completion of its acquisition of Solus Biotech. The South Korean actives manufacturer will expand Croda’s Asian manufacturing capability and create a new biotechnology R&D hub in the region.

THE DETAILS Solus’ innovative phospholipids will be incorporated into Croda’s skin care and hair care franchises within the UK specialty chemicals manufacturer’s Personal Care portfolio.

THE WHY? The acquisition of Solus Biotech will enhance Croda’s synthetic ceramides portfolio, delivered by Sederma, drawing on Solus’ existing biotech-derived ceramide and phospholipid technologies. Representing the Sederma business, the Global Business Director Luc Emprin, comments “This is a very exciting opportunity for Croda. Our existing ceramides, currently from Sederma, will be complemented by these natural fermentation-derived ceramides, furthering our portfolio of high efficacy science-based ingredients. We are pleased to add Solus’ manufacturing site in South Korea to our operations, furthering our growth strategy for this key region. Innovation synergies between our different R&D labs will bring additional technical value and business opportunities for our customers all over the world.”